Eli Lilly and Company Net Tangible Assets

Eli Lilly and Company posts a net tangible assets of $34B as of June 2026. That compares with $18B in the prior-year period — up 84.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Eli Lilly and Company's net tangible assets was $18B. The latest reading is $34B — a 84.6% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Net Tangible Assets is one piece of Eli Lilly and Company's financial statement story. At $34B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LLY.DE's net tangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Eli Lilly and Company's other metric pages and overview cover the third.

Judging Eli Lilly and Company against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in net tangible assets easier to interpret. Start with $34B here, then scan peer and history charts to see if the gap is persistent.